London Daily

Focus on the big picture.
Monday, Oct 05, 2026

Djokovic-backed ‘biotech’ firm’s approach likened to homeopathy

Djokovic-backed ‘biotech’ firm’s approach likened to homeopathy

Exclusive: QuantBioRes says it designs treatments for viral diseases based on electromagnetic frequency
A Danish “biotech” company in which Novak Djokovic holds a majority stake is working on a “frequency” treatment for 1Covid1-19 that an expert says bears similarities to the principles of homeopathy.

The world No 1 men’s tennis player was forced to leave Australia on Sunday after the country’s immigration minister cancelled his visa on the basis that his presence in Australia might risk “civil unrest” as he is a “talisman of anti-vaccination sentiment”.

On Wednesday it emerged Djokovic had acquired an 80% stake in QuantBioRes, the website of which says it designs treatments for viral diseases and resistant bacteria through “predicting the electromagnetic frequency” that can interfere with a virus’s activity.

“At QuantBioRes, we work in utilising unique and novel Resonant Recognition Model … a biophysical model based on findings that certain periodicities/frequencies within the distribution of energies of free electrons along the protein are critical for protein biological function and interaction with protein receptors and other targets,” the website says.

It carries a quote from the Serbian-American scientist Nikola Tesla: “If you wish to understand the universe, think of energy, frequency and vibration.”

Dr Darren Saunders, an Australian biomedical scientist, said the approach described on the QuantBioRes website was reminiscent of homeopathy, an alternative and unproven treatment that claims illness-causing substances can, in minute doses, treat people who are unwell.

Homeopaths claim that by diluting these substances in water or alcohol, the resulting mixture retains an “imprint” of “frequency” of the original substance that triggers a healing response in the body by causing an energetic shift.

Saunders said in his opinion it was “a stretch” for QuantBioRes to call itself a biotech company. “The ‘innovative technology’ they describe on their website does not reflect contemporary understanding of how biochemistry works,” Saunders said. “If any athletes or other potential investors would like advice on not blowing their cash on this stuff, my fees are reasonable.”

The website says the company will “soon start testing different treatment approaches”, but a link encouraging people to “learn more” appeared to be broken when the Guardian attempted to access it. A link to a July 2020 announcement that QuantBioRes would test 1Covid1-19 deactivation mechanisms also appeared to be broken.

Prof Peter Collignon, an infectious diseases physician and antimicrobial resistance expert, said the QuantBioRes website used “fancy terms” without providing any evidence of success of the methods it promoted. “They’ve given nothing in the way of data,” he said. “People are looking out for new molecules all the time, but the website describes a way of finding a new molecule without providing any evidence of success.”

The chief executive of QuantBioRes, Ivan Loncarevic, denied that the methods developed by his company had anything to do with homeopathy, and defended the lack of data on the company’s website.

“What we do has absolutely nothing to do with homeopathy,” he said in an interview. “The theory behind homeopathy is that you can transfer information from a chemical to another substance, such as water. What we do is to develop peptides with specific functionality. This is pure, classical science.

“Of course we are not putting our data on our website for every idiot to look at. We will soon publish an article in a scientific journal that will collect all our clinical testing.”

When asked when the article would be published, Loncarevic said: “With a little luck, in two to three months, after peer review.”

Asked about Saunders’ opinion that it was “a stretch” for QuantBioRes to call itself a biotech company and that the “innovative technology” described on its site did not reflect contemporary understanding of how biochemistry worked, Loncarevic replied: “That’s because we are innovative.”

He said other pioneers in engineering or science, such as Elon Musk and Galileo, had faced similar criticism when first airing their views. On the subject of broken links, he said this was the first time he had heard of the problem and “it’s not [done] on purpose”.
Newsletter

Related Articles

0:00
0:00
Close
BT Accused of Pressuring Vulnerable Customers During Digital Landline Shift
British Carmakers Warn of Growing Pressure From EU-China Tariff Dispute
Green Party of England and Wales Adopts Motion Defining Zionism as Racism
Medical Charity Threatens NHS Legal Action Over Two-Year Autism and ADHD Assessment Waits
British Transport Police Report Record Rise in Violence on Railways
Glasgow Council Workers Face Pay Cuts Under Fire-and-Rehire Plan
British Medical Groups Press Prime Minister Andy Burnham to Cancel £330 Million Palantir NHS Contract
UK Faces Record Bluetongue Outbreak Across Livestock Farms
UK Schools Report Thousands of Child-on-Child Sexual Offences
High Court Overturns Ban Blocking Gaza Families From Reuniting With Relatives in UK
G7 Authorizes Emergency Fuel Release as UK Diesel Prices Hit £2 a Litre
France and Italy Draw 1-1 in Nations League Match
Pope Leo XIV and Prince Albert II of Monaco Meet in Metz
SNCF Expands Low-Cost Ouigo High-Speed Service Between Lyon and Bordeaux
Paris Expands Dedicated Cargo Bike Routes for Urban Deliveries
French Film Industry Pushes for Tighter Streaming Investment Rules
Marseille Court Hands Down Prison Terms in Public Procurement Corruption Case
LVMH and Kering Rely on US Demand as Chinese Luxury Spending Slows
Toulouse Aerospace Sector Launches €80 Million Modernization Fund
Javier Milei Courts French Investment in LNG and Lithium
Mistral AI Launches Sovereign Model for European Public Services
French Competition Authority Fines Retailers €40 Million Over Misleading Promotions
France Records Exceptional Electricity Exports as Nuclear Output Recovers
Dassault Aviation Expands Rafale Assembly Capacity at Mérignac
Sanofi Invests €1 Billion in New Biologics Production Hub Near Lyon
France Protests Germany’s Extension of Border Controls Into 2027
French Public-Sector and Transport Unions Threaten National Strike
France Deploys Riot Police After Violence in Lyon Suburbs
French Anti-Terrorism Prosecutors Investigate Radicalized Flydubai Co-Pilot
France’s Defense Budget Surpasses NATO’s 2% of GDP Target
French Government Faces No-Confidence Threat Over Budget
France and G7 Release 100 Million Barrels From Strategic Oil Reserves
France Convenes Emergency Defense Council Over Threats to Commercial Shipping
France and Germany Coordinate Military Response After Russian Strikes on Kyiv Infrastructure
UK Police Release Six Iranian Nationals on Bail After RAF Fairford Security Alert
UK Business Confidence Falls as Energy Costs and Tax Uncertainty Rise
Cornwall Insight Warns UK Energy Bills Could Rise 16% in January
UK Introduces Zero VAT on Household Electricity Bills
UK 30-Year Gilt Yield Hits 6% as Bond Market Pressures Intensify
UK Introduces Stricter Subcontractor Checks and Expanded Trade Union Access
Green Party Proposes Three-Year Emergency Freeze on Private Rent Increases
UK Treasury Committee Seeks Tax Clarification Over Manchester City Investigation
Royal Marines Deploy to Faroe Islands for Northern European Security Exercise
UK Business Confidence Weakens as High Costs Delay Investment
UK GDP Growth Revised Up to 0.5% in Second Quarter
Bank of England Warns of Financial Stability Risks From Autonomous AI
UK Expands Early Prisoner Release Scheme to Ease Overcrowding
UK Records Worst Bluetongue Outbreak on Record Across Livestock Farms
UK Government Faces Shrinking Fiscal Headroom Ahead of October 28 Budget
UK 30-Year Gilt Yield Reaches 6% as Energy Shock Drives Borrowing Costs Higher
×